EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

By William Pao, Vincent A. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, Bhuvanesh Singh, R. Heelan, V. Rusch, L. Fulton and 5 more. Proceedings of the National Academy of Sciences of the United States of America, 2004

3,941 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/24811c3347c1a54faea85a73e0c6b38d00c8e2e7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. William Pao
2. P. Jänne
3. Gregory Riely
4. Adi F. Gazdar
5. Vincent A. Miller
6. M. Kris
7. C. Zappa
8. Christopher Sander

In Pulmonary and Respiratory Medicine

1. William Pao
2. Adi F. Gazdar
3. P. Jänne
4. Gregory Riely
5. Vincent A. Miller
6. B. Hughes
7. B. Chan
8. M. Kris

Citations in the corpus

• Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. (2007, background): “In particular, the L858R mutant is 10- to 100-fold more sensitive to erlotinib and gefitinib than the wild-type kinase (Pao et al., 2004; Greulich et al., 2005; Mukohara et al., 2005) and significantly more sensitive than the G719S mutant (Jiang et al., 2005).”